Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) delivers transformative intelligence through market-leading platforms like Web of Science™ and Cortellis™, powering innovation across academia, intellectual property, and life sciences. This news hub provides investors and professionals with direct access to official announcements shaping global research and commercialization efforts.
Track critical updates including quarterly earnings disclosures, strategic partnerships, product launches, and regulatory filings. Our curated feed ensures timely access to press releases about AI-driven analytics advancements, IP portfolio developments, and expansions in pharmaceutical intelligence solutions.
Key content categories include financial performance reports, acquisition announcements, leadership updates, and innovations in real-world data applications. Bookmark this page to monitor Clarivate's progress in converting transactional revenues to high-margin subscriptions while maintaining its position as a critical enabler of R&D workflows.
Clarivate (NYSE:CLVT) has announced the integration of Pathway Maps into its OFF-X translational safety intelligence solution. This enhancement aims to streamline safety evaluations in drug development, addressing the critical issue where over 30% of drug development failures are attributed to safety concerns.
The new Pathway Maps feature provides visual tools that combine disease-specific signaling pathways and molecular processes with curated safety data, enabling researchers to quickly identify potential safety liabilities. This integration helps research teams make faster, more informed decisions during the drug development process, from early discovery to post-marketing surveillance.
The enhanced OFF-X platform, when combined with Cortellis Drug Discovery Intelligence, offers researchers a comprehensive approach to evaluate both efficacy and safety in drug development, helping reduce costly late-stage failures and accelerate time to market.
Clarivate reported mixed Q1 2025 financial results with total revenues of $593.7 million, down 4.4% from Q1 2024, while organic revenues showed a modest 0.3% increase. The company posted a net loss of $103.9 million ($0.15 per share), compared to a $75.0 million loss in Q1 2024.
Key highlights include:
- Organic recurring revenue growth of 0.6%
- Adjusted EBITDA of $233.2 million
- Free cash flow of $110.3 million
- $50 million in share repurchases
The company reaffirmed its 2025 outlook, projecting revenues between $2.28-2.40 billion and organic ACV growth of 1.0-2.0%. Despite macro volatility, management reported successful execution of their Value Creation Plan, with improved renewal rates and higher product usage in key areas.
Clarivate (NYSE: CLVT) has launched DRG Commercial Analytics 360, a new solution designed to help medtech companies enhance their commercial strategies through advanced data analytics. The platform combines Procedure Finder's search capabilities with Clarivate's provider and affiliations network to deliver comprehensive real-world intelligence.
The solution offers several key features:
- Integrated healthcare provider data and analytics for understanding patient treatment patterns and network affiliations
- De-duplicated market segments for accurate procedure volume tracking
- 360-degree market visibility with modularized claims and code groupings
- Expert-led data intelligence backed by medtech and healthcare specialists
The platform aims to help medtech companies optimize targeting, strategic planning, and patient access while enabling data-driven decision-making across commercial organizations.
Clarivate (NYSE: CLVT) has launched EndNote 2025, an enhanced reference management solution featuring AI-powered capabilities. The new release includes several key features: an AI-powered Key Takeaway tool for extracting research insights, an improved journal publishing matching tool, PDF citation functionality, and a redesigned summary panel.
Notable additions include Web of Science citing articles integration, streamlined reference updates, and full-text access tools. The company plans to introduce more AI features later in 2025, including the EndNote Research Assistant for subscribers. The solution operates on Clarivate's Academic AI Platform, facilitating AI deployment across their product portfolio.
Clarivate has announced a major expansion of its Academic AI Platform, introducing AI Agents to enhance academic workflows starting April 2025. The platform will feature new AI Agents, an Agent Builder, and community tools designed to boost productivity for researchers, students, and staff.
The first series of AI Agents includes a Literature Review tool launching April 10, 2025, through Web of Science Research Assistant, and Research Intelligence capabilities available to development partners by August 2025. The platform builds upon existing AI-powered tools already adopted by over 3,000 institutions.
The initiative includes development of an Agent Builder, a flexible environment requiring minimal coding expertise, allowing institutions to create and customize their own AI tools. The platform will also support community-built AI solutions, enabling institutions to share and collaborate on AI development.
Clarivate (NYSE: CLVT) has announced it will release its first quarter 2025 financial results on Tuesday, April 29, 2025, before market opening. The company will host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results.
The earnings release and supplementary financial information will be available on Clarivate's investor relations website. Interested parties can join the live webcast through the investor relations section or participate in the audio broadcast by calling 800-715-9871 (U.S.) or +1 646-307-1963 (international) using conference ID 7007526.
A replay of the webcast will be accessible on the investor relations website two hours after the call concludes and will remain available for one year.
Clarivate (NYSE:CLVT) has announced a strategic partnership with Iprova, integrating Iprova's invention creation solutions with IPfolio, Clarivate's IP management software. The partnership coincides with the release of Invention Studio 3, Iprova's enhanced AI-based invention creation tool hosted on Microsoft Azure.
The integration aims to streamline the transition of inventions into the patent workflow, creating a more collaborative environment for inventors and attorneys. The partnership represents Clarivate's commitment to improving the innovation economy by connecting knowledge and intellectual capital.
Additionally, Clarivate has acquired Rowan Patents, an AI-driven patent drafting software, further strengthening its position as a central hub for IP management. These strategic moves enhance Clarivate's ability to provide comprehensive support throughout the IP lifecycle, from invention creation to patent filing and prosecution.
Clarivate has unveiled its 2025 Top 100 Global Innovators list, highlighting organizations leading worldwide technology research and innovation. These elite companies generate $4.6 trillion in annual revenues, representing 4.4% of the global economy, with average innovation investment of 8.8% of their revenues totaling $290 billion USD.
Key findings include:
- Japan leads with 33 organizations, followed by US (18), Taiwan (13), Germany and South Korea (8 each)
- Samsung Electronics maintains #1 ranking
- Six new companies joined the list, including GE Aerospace and Caterpillar
- 16 organizations maintained all-time recipient status
New analysis reveals convergent inventions account for almost 40% of top innovations across five macro-forces: sustainability, wellbeing, mobility, connectivity, and automation. Electronics and computing equipment sector leads, followed by Semiconductors and Industrial systems.
Clarivate (NYSE: CLVT) has published a white paper analyzing the pharmaceutical industry's growth potential in Latin America. The report, titled 'How is Latin America Growing?', highlights that the region's pharmaceutical market, valued at $98 billion, is projected to grow by 10.1% between 2021 and 2025.
The study emphasizes key areas for development including strategic partnerships, local API production, and regulatory modernization. Insights were gathered from discussions at the 2023 Summit LATAM in Barcelona and 2024 Summit LATAM at CPhI Milan, focusing on collaboration between industry stakeholders, government agencies, and academia.
The report outlines critical findings including: the need for transparency in partnerships, potential of local API production to reduce import dependence, AI's role in modernizing regulatory processes, and importance of consistent policies for investment and innovation.
Clarivate (NYSE: CLVT) reported Q4 2024 results with total revenue of $663.0 million, down 3.0% from Q4 2023, with organic revenues declining 0.7%. The company posted a Q4 net loss of $191.8 million ($0.27 per share), improving from a loss of $843.9 million in Q4 2023.
For full-year 2024, revenue was $2.56 billion, down 2.7% from 2023, with organic revenues decreasing 1.4%. The company generated $357.5 million in free cash flow and executed $200 million in share repurchases and $198.1 million in debt pre-payment. The board authorized a new $500 million share repurchase program for 2025-2026.
Looking ahead to 2025, Clarivate expects revenues between $2.28B-$2.40B, with recurring organic revenue growth between -1.0% to 1.0%. The company has initiated a strategic review, including potential divestitures, and plans to discontinue certain low-margin transactional products in 2025-2026.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
